Open AccessCan glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors help in mitigating the risk of atrial fibrillation in patients with diabetes?
Author(s) -
Sahith Reddy Thotamgari,
Udhayvir Singh Grewal,
Aakash Sheth,
Akhilesh Babbili,
Paari Dominic
Publication year - 2022
Publication title -
cardiovascular endocrinology and metabolism
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.498
H-Index - 8
ISSN - 2574-0954
DOI - 10.1097/xce.0000000000000265
Subject(s) - adverse event reporting system , medicine , dipeptidyl peptidase 4 , liraglutide , atrial fibrillation , glucagon like peptide 1 , adverse effect , diabetes mellitus , glucagon like peptide 1 receptor , confidence interval , dipeptidyl peptidase , pharmacology , type 2 diabetes , endocrinology , receptor , biochemistry , agonist , chemistry , enzyme